Faeth Therapeutics Financial Results
Faeth Therapeutics reported third quarter 2026 financial results, ending the period with $174.8 million in cash and marketable securities. The company highlighted the receipt of FDA Fast Track designation for its lead program PIKTOR in endometrial cancer and expects topline Phase 2 data by year-end 2026.
- Term
- Q3 2026
“We designed PIKTOR, an all-oral, multi-node inhibitor, to address those limitations, and we believe it has the potential to give patients a differentiated treatment option. We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer by year-end, and to reporting initial safety and efficacy data from our PIK-101 trial in HR+/HER2- breast cancer in 2027.”
Anand Parikh, Chief Executive Officer